S-5498-119
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Sponsored by Mark Warner (D-VA)
What it does
The bill would amend the Federal Food, Drug, and Cosmetic Act to add galactose-alpha-1,3-galactose ("alpha-gal") to the definition of "major food allergen." The definition would include ingredients derived from non-catarrhine primate mammals and red algae in the order Gigartinales. It would not include mammal-derived ingredients that the Secretary determines have no alpha-gal above an established, detectable limit, such as those from alpha-gal-knockout mammals. The change would apply beginning 18 months after enactment.
Who benefits
People with alpha-gal syndrome, a tick-linked allergy to a sugar found in most mammal-derived products, who may find it easier to identify problem ingredients on labels. Their families and caregivers, who may spend less effort checking ingredients. Allergists and emergency clinicians who may see fewer accidental reactions. Producers of alpha-gal-knockout mammal ingredients, who could gain an exemption path if the Secretary makes a qualifying determination.
Who is hurt
Food, supplement, and drug-adjacent manufacturers that use mammal-derived ingredients or red algae (such as carrageenan) and may face relabeling, testing, and supply-chain compliance costs. Smaller producers with fewer compliance resources may bear proportionally larger burdens. Consumers may see higher prices if costs are passed on. FDA would need resources to implement the definition and make determinations about detectable limits. Producers who cannot show an ingredient falls under the exemption could face labeling or enforcement exposure.
Supporters argue
Supporters argue that alpha-gal syndrome can cause serious reactions, including anaphylaxis, and that people with it currently lack the clear labeling that major-allergen status provides. They contend the 18-month delay gives manufacturers time to adapt, and that the exemption for ingredients shown to lack detectable alpha-gal limits the burden on industry. They cite CDC reporting that thousands of cases have been identified in recent years, with the affected area expanding.
Opponents argue
Opponents argue that alpha-gal differs from existing major allergens because reactions are often delayed and dose-dependent, and that labeling rules built for proteins may not fit a sugar molecule. They contend that including red algae and broad categories of mammal-derived ingredients could force costly relabeling and testing, and that detection standards remain unsettled. They cite the lack of validated testing methods and the burden on small producers.
Constitutional context
Congress regulates food labeling and products in interstate commerce under the Commerce Clause (Art. I, §8, cl. 3), a power long upheld for food and drug regulation (for example, Wickard v. Filburn (1942) on the breadth of commerce authority). The bill raises no distinct constitutional question beyond that regulatory authority.
Checks and balances
Congress would set the definition, and the HHS Secretary (through FDA) would gain a determination role on detectable limits, subject to judicial review of agency actions.
Historical precedent
The Food Allergen Labeling and Consumer Protection Act of 2004 created the major-allergen labeling framework, and the FASTER Act of 2021 added sesame to the definition.